Skip to main content
. 2022 Apr 1;28(11):2237–2247. doi: 10.1158/1078-0432.CCR-21-2326

Figure 5.

Figure 5. rPFS by PTEN (IHC) assay. A, The PFS of samotolisib + enzalutamide arm versus placebo + enzalutamide arm in patients with PTEN loss. B, The PFS of samotolisib + enzalutamide arm versus placebo + enzalutamide arm in patients without PTEN loss.

rPFS by PTEN (IHC) assay. A, The PFS of samotolisib + enzalutamide arm versus placebo + enzalutamide arm in patients with PTEN loss. B, The PFS of samotolisib + enzalutamide arm versus placebo + enzalutamide arm in patients without PTEN loss.